Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1675
This examiner grants 56% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19329417 | CELL-PENETRATING PEPTIDE COMPOUNDS | Non-Final OA | Ohio State Innovation Foundation |
| 19310993 | SEMAGLUTIDE FOR USE IN MEDICINE | Non-Final OA | Novo Nordisk A/S |
| 17247153 | Methods for Inducing Intermittent Fasting and Modulating Autophagy | Non-Final OA | The Chinese University of Hong Kong |
| 16427593 | Composition and Application of Arginine-depleting Agents for Cancer, Obesity, Metabolic Disorders, and Related Complications and Comorbidities | Non-Final OA | The Chinese University of Hong Kong |
| 17548332 | FORMULATIONS FOR NUTRITIONAL SUPPORT IN SUBJECTS IN NEED THEREOF | Final Rejection | ByHeart, Inc. |
| 17155759 | FORMULATIONS FOR NUTRITIONAL SUPPORT IN SUBJECTS IN NEED THEREOF | Non-Final OA | ByHeart, Inc. |
| 17275764 | METHODS AND COMPOSITIONS FOR TREATING SKIN DISEASES | Non-Final OA | VANDERBILT UNIVERSITY |
| 18313856 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS | Non-Final OA | The Regents of the University of Michigan |
| 17266897 | TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18199523 | COMPOSITIONS AND METHODS USING A COMBINATION OF AUTOPHAGY INDUCER AND HIGH PROTEIN FOR INDUCTION OF AUTOPHAGY | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 16954694 | COMPOSITIONS AND METHODS USING A COMBINATION OF AUTOPHAGY INDUCER AND HIGH PROTEIN FOR INDUCTION OF AUTOPHAGY | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 17995194 | FACTOR B INHIBITORS AND USES THEREOF | Final Rejection | The Trustees of the University of Pennsylvania |
| 17925455 | Methods and Compositions for Treatment of Age-Related Dysfunction | Final Rejection | The University of Tokyo |
| 17767859 | ANTI-CANCER LEUCINE-RICH PEPTIDES AND USES THEREOF | Non-Final OA | KING'S COLLEGE LONDON |
| 18172333 | NOVEL DOPAMINE PRECURSORS | Non-Final OA | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
| 17283315 | Selective Binding and Aggregation of Human Keratin in the Skin Barrier Using Human Filaggrin Subdomains SD67 and SD150 | Final Rejection | YALE UNIVERSITY |
| 18032018 | METHODS OF TREATING, AMELIORATING, AND/OR PREVENTING COVID-19 INFECTION AND RELATED INFLAMMATION | Non-Final OA | Rowan University |
| 17188805 | GIP PEPTIDE ANALOGUES | Non-Final OA | University of Copenhagen |
| 17997038 | ANTIVIRAL BIOMIMETIC PEPTIDES AND USES THEREOF | Non-Final OA | VIRGINIA COMMONWEALTH UNIVERSITY |
| 18675958 | CD71 BINDING FIBRONECTIN TYPE III DOMAINS | Non-Final OA | Aro Biotherapeutics |
| 16008281 | FKBP DOMAIN WITH TRANSGLUTAMINASE RECOGNITION SITE | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 16956637 | PROTEIN HYDROLYSATE AND PROCESS FOR MAKING SUCH | Final Rejection | Tessenderlo Group NV |
| 16617497 | USE OF CITRULLINE AND GLUTATHIONE TO INCREASE MUSCLE MASS | Non-Final OA | KYOWA HAKKO BIO CO., LTD. |
| 18030174 | GRIFFITHSIN FOR RHABDOVIRIDAE INFECTIONS | Non-Final OA | University of Louisville Research Foundation, Inc. |
| 18007323 | NUTRITION FORMULATION | Non-Final OA | OTSUKA PHARMACEUTICAL FACTORY, INC. |
| 17581617 | IMMUNOTHERAPY FOR POLYOMAVIRUSES | Final Rejection | The Council of the Queensland Institute of Medical Research |
| 18543196 | USE OF LOW VOLUME PLASMA EXCHANGE FOR TREATING THE EARLY AND MIDDLE STAGES OF ALZHEIMER'S DISEASE | Non-Final OA | Grifols Worldwide Operations Limited |
| 18004231 | COMPOSITIONS HAVING NEUROREGENERATIVE APPLICATIONS | Non-Final OA | GRIFOLS WORLDWIDE OPERATIONS LIMITED |
| 18505472 | WIDE-SPECTRUM ANTIBACTERIAL PHARMACEUTICAL FORMULATIONS COMPRISING LYSOZYME AND METHODS OF USING THE SAME | Final Rejection | AYBAR ECOTECHNOLOGIES CORP. |
| 18495355 | POLYPEPTIDE FOR USE IN THE PROTECTION OF OXYGEN SENSITIVE GRAM-POSITIVE BACTERIA | Final Rejection | THE HEALTHY AGING COMPANY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy